Researchers from Ileadbms Co. Ltd. presented the discovery and preclinical characterization of IL-21120033, a new CXCR7 agonist being developed for the treatment of inflammatory bowel disease.

For example, we have our ACKR3 antagonist former called CXCR7 antagonist for progressive multiple sclerosis. This first-in-class compound showed in every one of the preclinical tests we did ...

Idorsia’s operating loss halved to CHF 308 million in 2024. QVIVIC sales nearly doubled, reaching CHF 61 million. The stock fell by 7.59% post-earnings. Strategic cost reductions included a ...

Idorsia’s operating loss halved to CHF 308 million in 2024. QVIVIC sales nearly doubled, reaching CHF 61 million. The stock fell by 7.59% post-earnings. Strategic cost reductions included a ...

Sepsis is a life-threatening clinical syndrome characterized by multiorgan dysfunction caused by a dysregulated or over-reactive host response to infection. During sepsis, the coagulation cascade is ...